Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody
1996

Reducing Immunogenicity of a Clearing Agent for Antibody Therapy

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): D Marshall, RB Pedley, JA Boden, R Boden, RG Melton, RHJ Begent

Primary Institution: Cancer Research Campaign Laboratories, Department of Clinical Oncology, Royal Free Hospital School of Medicine, London

Hypothesis

Can polyethylene glycol (PEG) modification reduce the immunogenicity of a galactosylated streptavidin clearing agent without affecting its effectiveness?

Conclusion

PEG modification successfully reduced the immunogenicity of the galactosylated streptavidin clearing agent, but it also inhibited effective clearance of the antibody from circulation.

Supporting Evidence

  • PEG modification reduced the immune response in mice after injection of gal-streptavidin.
  • 2.5 PEG gal-streptavidin showed a lower anti-gal-streptavidin response compared to unmodified gal-streptavidin.
  • 5 PEG gal-streptavidin resulted in very low levels of anti-gal-streptavidin antibodies in most mice.

Takeaway

Scientists wanted to make a medicine that helps clear cancer-fighting antibodies from the body without causing allergic reactions. They found that adding a special chemical made it less likely to cause allergies, but it also made the medicine work less well.

Methodology

Mice were injected with either gal-streptavidin or PEG-modified gal-streptavidin, and their immune responses were measured through antibody titres over time.

Limitations

The study was conducted in mice, and the effects in humans may differ; also, the degree of PEG modification may affect the results.

Participant Demographics

Immunocompetent mice were used in the study.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication